Friday, May 23, 2025 7:23:05 AM
💥Separately, another recent study, in the journal Discover Oncology, concluded that a variety of cannabinoids —-including delta-9 THC, CBD and cannabigerol (CBG)—“SHOW PROMISING POTENTIAL AS ANTICANCER AGENTS THROUGH VARIOUS MECHANISMS,” for example by limiting the growth and spread of tumors.
Other recent research on the possible therapeutic value of lesser-known compounds in cannabis found that a number of minor cannabinoids may have anticancer effects on blood cancer that warrant further study.
“Consistent with the latest findings, that study found cannabis showed potential in slowing the growth of cancer cells and even killing cancer cells in certain cases.”
“A scientific review of CBD last year also touched on “the diverse anticancer properties of cannabinoids”that the authors said present “promising opportunities for future therapeutic interventions in cancer treatment.”
https://www.marijuanamoment.net/medical-marijuana-could-increase-efficacy-of-chemotherapy-to-fight-cancer-while-reducing-side-effects-study-suggests/
https://jbmps.com.br/jbmps/article/view/4
Other recent research on the possible therapeutic value of lesser-known compounds in cannabis found that a number of minor cannabinoids may have anticancer effects on blood cancer that warrant further study.
“Consistent with the latest findings, that study found cannabis showed potential in slowing the growth of cancer cells and even killing cancer cells in certain cases.”
“A scientific review of CBD last year also touched on “the diverse anticancer properties of cannabinoids”that the authors said present “promising opportunities for future therapeutic interventions in cancer treatment.”
https://www.marijuanamoment.net/medical-marijuana-could-increase-efficacy-of-chemotherapy-to-fight-cancer-while-reducing-side-effects-study-suggests/
https://jbmps.com.br/jbmps/article/view/4
Bullish
Recent CVSI News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/15/2025 09:25:41 PM
